Search Results
Your search for ,led matches 5950 pages
Showing 5251 - 5300Palbociclib as Initial Endocrine-Based Therapy in Postmenopausal Women With Metastatic Breast Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 3, 2015, palbociclib (Ibrance) was granted...
Improving the Quality of Palliative Care in Oncology
Two years ago, ASCO collaborated with the American Academy of Hospice and Palliative Medicine to develop the Virtual Learning Collaborative, a virtual quality improvement program intended to address the complex care needs of patients with advanced cancer and the care quality for all patients with...
The Current State of Hematologic Malignancies
Due in part to the refinement of bone marrow transplantation and its many innovations, some leukemias that once were death sentences now have cure rates of up to 90%. As research in transplantation and other promising areas accelerates, we are on the verge of breaking new clinical boundaries in...
First-Line Crizotinib Improves Progression-Free Survival vs Chemotherapy in ALK-Positive NSCLC
In a phase III trial (PROFILE 1014) reported in The New England Journal of Medicine, Benjamin J. Solomon, MB, BS, PhD, of Peter MacCallum Cancer Centre, Melbourne, and colleagues found that the ALK inhibitor crizotinib (Xalkori) improved progression-free survival vs standard chemotherapy in...
Lenvatinib in Advanced Radioiodine-Refractory Differentiated Thyroid Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 13, 2015, lenvatinib (Lenvima) was approved for the...
Nivolumab Shows Activity in Previously Treated Metastatic Renal Cell Carcinoma
In a randomized phase II trial reported in the Journal of Clinical Oncology, Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues found that the programmed cell death protein-1 (PD-1) immune checkpoint inhibitor antibody nivolumab (Opdivo) was associated with...
Big Data and the Promise of Precision Medicine in Cancer
Precision medicine—and its promise to revolutionize how we understand disease and care for our patients—is a concept that oncology has understood and embraced for well over a decade. But millions of Americans recently heard about the concept for the first time when President Obama announced a...
ASCO Commends Dr. Varmus for Outstanding Leadership
Following news of Dr. Varmus’ planned departure from the National Cancer Institute (NCI), ASCO issued the following statement: ASCO is enormously grateful for the service and leadership of Harold Varmus, MD, as Director of the National Cancer Institute [NCI]. During Dr. Varmus’ tenure, the...
Harold Varmus, MD, Steps Down as NCI Director, Douglas Lowy, MD, Named Acting Director
Harold Varmus, MD, who has led the National Cancer Institute (NCI) at the National Institutes of Health (NIH) for nearly 5 years, has announced that he will step down from his post, effective March 31, 2015. “It has been our great fortune to have Dr. Varmus at the helm of the NCI,” said NIH...
Herbal Supplements: Increasing Problems
In Don Quixote, the 1605 Spanish literary masterpiece by Miguel Cervantes, “Balsam of Fierabras” is mentioned often as a therapeutic panacea. It calls for mixing rosemary, wine, oil, and salt. As the story goes, the knight relied heavily on this herbal preparation to relieve him of pain from the...
New Oncology Care Model: Encouraging Better Coordination for Cancer Care
On February 12, 2015, the U.S. Department of Health and Human Services (HHS) announced its new Oncology Care Model, a multipayer payment and care delivery model intended to support better coordination for cancer care. The initiative will include 24-hour access to practitioners for beneficiaries...
Panobinostat in Combination With Bortezomib‑Dexamethasone in Previously Treated Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 23, 2015, panobinostat (Farydak) was granted...
Increasing the Use of Hypofractionated Radiation in Early-Stage Breast Cancer: The Way Forward
Bekelman and colleagues are to be congratulated on the publication of an important paper—reviewed in this issue of The ASCO Post—alerting us all to the underutilization of hypofractionated whole-breast irradiation in the treatment of early-stage breast cancer.1 As background, recent randomized...
Many Cancer Patients at Risk for Hepatitis B Virus Reactivation
In 2015, no cancer patients should be cured of their malignancy only to die of reactivation of hepatitis B virus (HBV),” according to Anna S. Lok, MD, the Alice Lohrman Andrews Research Professor in Hepatology and Director of Clinical Hepatology at the University of Michigan, Ann Arbor. “I...
AACR Names Nancy E. Davidson, MD, President-Elect for 2015–2016
The American Association for Cancer Research (AACR) has announced the election of Nancy E. Davidson, MD, Director of the University of Pittsburgh Cancer Institute and UPMC CancerCenter in Pittsburgh, as its President-Elect for 2015–2016. Dr. Davidson will officially become President-Elect at the...
No Survival Benefit Reported With Docetaxel Added to Hormone Therapy in Metastatic Prostate Cancer
Docetaxel added to androgen-deprivation therapy did not improve overall survival over androgen-deprivation therapy alone in hormone-naive metastatic prostate cancer, according to an updated analysis of the GETUG-AFU 15 trial presented at the 2015 Genitourinary Cancers Symposium.1 In a retrospective ...
Our Aging Population: Challenges in Caring for Older Patients With Cancer
Managing older-aged cancer patients represents one of the major challenges to our health-care system. Caring for older cancer patients, with their frequent multiple morbidities and a variable health status, requires special integration of an oncologic and geriatric approach. Moreover, our aging...
Intensified Immunotherapy Encouraging in Chemotherapy-Naive Metastatic Prostate Cancer
Emerging evidence suggests that immunotherapy may play an important role in treating prostate cancer. In particular, preliminary results have shown that combining a new vaccine with ipilimumab (Yervoy) boosts overall survival in men with castration-resistant prostate cancer.1 A study comparing...
Targeted MR/Ultrasound Fusion–Guided Biopsy Increased Detection of High-Risk Prostate Cancer
Among men undergoing biopsy for suspected prostate cancer, targeted magnetic resonance (MR)/ultrasound fusion–guided biopsy was associated with an increased rate of detection of high-risk prostate cancer and a decreased rate of detection of low-risk prostate cancer than was standard...
Shining a Spotlight on Epithelioid Hemangioendothelioma
In the winter of 2013, my son, Dmitriy, now 26, had a cough that wouldn’t go away. After several rounds of antibiotics failed to halt the persistent problem, a pulmonologist we consulted ordered a chest x-ray, which showed a large tumor lodged between Dmitriy’s lungs. Although the doctor said the...
Nivolumab in Metastatic Squamous Non–Small Cell Lung Cancer After Platinum Therapy
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 4, 2015, the anti–programmed cell death protein 1 (PD-1) ...
Increased Progression-Free Survival With Addition of Carfilzomib to Lenalidomide/Dexamethasone in Relapsed Multiple Myeloma
In a planned interim analysis of the phase III ASPIRE trial reported in The New England Journal of Medicine, A. Keith Stewart, MB, ChB, of the Mayo Clinic, Scottsdale, Arizona, and colleagues found that the addition of the proteasome inhibitor carfilzomib (Kyprolis) to lenalidomide...
The Emerging Role of Radiation Therapy in Gastrointestinal Cancers
The use of radiation therapy in the treatment of gastrointestinal cancer has evolved over the past several decades, in a gradual, stepwise fashion. Since most gastrointestinal cancers are diagnosed at a locally advanced stage, coupled with the inherent sensitivity of most parts of the...
St. Jude Children’s Research Hospital Appoints Chair of Department of Radiation Oncology
St. Jude Children’s Research Hospital has named Thomas E. Merchant, DO, PhD, as Chair of the Department of Radiation Oncology. Dr. Merchant will hold the Baddia J. Rashid Endowed Chair in Radiation Oncology. “Dr. Merchant is a proven leader in pediatric radiotherapy and will be instrumental in...
Current Progress Against Cancer and What Lies Ahead in the Next Decade
In January, ASCO released its report, Clinical Cancer Advances 2015: An Annual Report on Progress Against Cancer,1 which details research advances over the past decade that have led to longer survival and better quality of life for the more than half-a-million people diagnosed with cancer each...
Breast Cancer Management in Review
Anyone who has attended the major oncology meetings knows that research from clinical trials in breast cancer often dominates the stage, with countless abstracts featuring new and updated results. To help the readers of The ASCO Post stay up to date with the latest discoveries and findings...
James P. Allison, PhD, Wins 2015 Paul Ehrlich and Ludwig Darmstaedter Prize
James P. Allison, PhD, Chair of Immunology at The University of Texas MD Anderson Cancer Center, has received the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize in recognition of his work in the field of immunotherapy. “In immunotherapy, it’s not the tumor but the immune system that is targeted....
Results of RTOG 0617 Reconsidered
Radiation Therapy Oncology Group (RTOG) 0617 was a study initially designed to address an important issue in radiation oncology regarding the treatment of stage III non–small cell lung cancer (NSCLC): Are outcomes improved with high-dose as opposed to standard-dose thoracic radiation therapy? The...
No Survival Benefit From Adjuvant Sorafenib or Sunitinib in Kidney Cancer
Adjuvant therapy with sorafenib (Nexavar) or sunitinib (Sutent) failed to make any inroads in improving disease-free survival in patients with locally advanced kidney cancer in the randomized, placebo-controlled, multicenter, phase III Adjuvant Sorafenib and Sunitinib for Unfavorable Renal...
Widespread Use of Docetaxel Preceded Phase III Evidence of Usefulness in Patients With Metastatic Prostate Cancer
Docetaxel was being widely used by patients with metastatic prostate cancer before phase III evidence that it was more effective than the standard of care for patients with castration-resistant prostate cancer, according to an analysis of Medicare claims from before and after the trial results and...
2015 Canada Gairdner Awards Honor Top Medical Researchers Worldwide
The Gairdner Foundation named the winners of the 2015 Canada Gairdner Awards, recognizing some of the most significant medical discoveries around the world. The awards provide a $100,000 (CAD) prize to each scientist for his or her work. The aim of the Gairdner Awards is to promote a culture of...
AACR Honors Cancer Pioneers at the 2015 Annual Meeting
The American Association for Cancer Research (AACR) recognized six oncologists making valuable contributions to their fields with awards at the Association’s Annual Meeting 2015, held in Philadelphia from April 18–22. William C. Hahn, MD, PhD, was awarded with the 39th Annual AACR–Richard and Hinda ...
Robert H. Lurie Names Associate Director for Administration
Aleksandar Zafirovski, MBA, has been named Executive Administrative Director and Associate Director for Administration for the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He has served as Interim Associate Director since 2014. Mr. Zafirovski has previously been...
Richard Gilbertson, MD, PhD, Leaves St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital announced the departure of Scientific and Comprehensive Cancer Center Director, Richard Gilbertson, MD, PhD. Dr. Gilbertson will be Director of the Cambridge Cancer Centre at the University of Cambridge. Since joining St. Jude in 2000, Dr. Gilbertson has led...
Staff Support Sessions in an Oncology Setting
Work-related issues such as coping skills, stress management, burnout, and compassion fatigue are among the challenges faced by clinical and other staff in cancer treatment centers. Given the emotional consequences of professional caregiving, staff support group meetings are valuable resources for...
Ann Partridge, MD, MPH, Confronts Challenges Facing Young Women With Breast Cancer With Support From Conquer Cancer Foundation Improving Cancer Care Grant
Ann Partridge, MD, MPH, Associate Professor of Medicine at Harvard Medical School and Founding Director of the Program for Young Women With Breast Cancer at the Dana-Farber Cancer Institute, received a 2010 Improving Cancer Care Grant (ICCG) for her project “Improving the Care of Young Women with...
Triple Negative Breast Cancer Foundation Works to Change the Treatment Landscape of an Aggressive Form of Breast Cancer
Hayley Dinerman, Cofounder and Executive Director of the Triple Negative Breast Cancer Foundation, remembers how she and a group of close female friends first learned about the devastating effects of triple-negative breast cancer. It was 2005 when these new mothers, who had recently formed a...
Michael E. Jung, PhD, Charles Sawyers, MD, and Howard I. Scher, MD, Receive Team Science Award From American Association for Cancer Research
Michael E. Jung, PhD, Distinguished Professor of Chemistry and Biochemistry and Member at UCLA Jonsson Comprehensive Cancer Center; Charles Sawyers, MD, Human Oncology and Pathogenesis Program Director at Memorial Sloan Kettering Cancer Center; and Howard I. Scher, MD, Chief of the Genitourinary...
Breast Cancer Management in Review
With the field of breast oncology as complex as ever, a brief update of the latest findings impacting breast cancer treatment seems timely. To that end, I have assembled highlights from a collection of newsworthy studies featured over the past year and into early 2015. Part 1 of this review, which...
How the International Innovation Grant Is Improving Cancer Care for Women in Myanmar
In 2014, the Conquer Cancer Foundation awarded four inaugural International Innovation Grants to aid novel research projects in Colombia, Myanmar, Nigeria, and Tanzania. The program, which supports a 1-year research grant of up to $20,000 to a nonprofit organization or governmental agency in a low- ...
Heal Thy Patient … Reflections on the Human Side of Medicine
The first time I met Mrs. X and her husband was to discuss the surgical treatment options for pancreatic cancer. She had just been diagnosed with pancreatic cancer at her local hospital and was being referred to a tertiary care center for operative management. Mrs. X and her husband were no...
Bombarded With Changes in Health Care and Beyond, Gynecologic Oncologists Prepare for the Challenges Ahead
Physicians are being “bombarded” with changes in health care and beyond, Richard R. Barakat, MD, FACS, noted in his Presidential Address at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. These changes are being precipitated by steeply rising health-care costs amid...
Researchers Discuss Pilot Study on Hallucinogenic Therapies for Cancer Anxiety
Although varying levels of existential distress are near-ubiquitous among patients with cancer, evidence-based interventions in this clinical area remain somewhat elusive. Seeking to explore novel approaches in the palliative care environment, New York University (NYU) School of Medicine principal...
Maintenance of Certification Activities: Earn Points at the ASCO Annual Meeting
The 2015 ASCO Annual Meeting will feature three activities to help attendees earn American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points while onsite. Annual Meeting Practice-Centered Session MOC Self-Assessment Activity This activity is designed for attendees who want ...
Combining Antiangiogenic and Vascular-Disrupting Agents Improves Progression-Free Survival in Persistent Ovarian Cancer
“Bevacizumab [Avastin] prevents new blood vessels from growing, but what about the blood vessels that are already in the tumor?” Presenting that challenge to participants at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Chicago, Bradley J. Monk, MD, of the University of...
NCCN Posters of Interest Included Studies in Kidney, Breast, and Endometrial Cancers, Melanoma, and Cost Issues
The quality and quantity of original research presented at the National Comprehensive Cancer Network (NCCN) Annual Conference continue to grow since poster sessions debuted a few years ago. The ASCO Post offers summaries for just a few that caught our eye, out of more than 65 presented this year....
José Baselga, MD, PhD, Inaugurated as AACR President
The American Association for Cancer Research (AACR) inaugurated José Baselga, MD, PhD, as President for 2015–2016 at the AACR Annual Meeting 2015. Dr. Baselga, an internationally recognized physician-scientist whose research focuses on the clinical development of novel molecularly targeted agents...
p53 Takes Center Stage
BOOKMARKTitle: p53: The Gene That Cracked the Cancer CodeAuthor: Sue ArmstrongPublisher: Bloomsbury PublishingPublication date: November 20, 2014Price: $19.98; hardcover, 288 pages Completed in April 2003, the Human Genome Project was one of the greatest feats of scientific exploration, an inward ...
People Living With HIV in the United States Have a 50% Excess Cancer Risk
The nearly 900,000 people in the United States living with diagnosed human immunodeficiency virus (HIV) infection have an excess cancer risk of 50%, according to a joint analysis of data by the National Cancer Institute and the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention,...
Remembering Mark R. Green, MD, a Leader in Lung Cancer Research and Treatment
Few people have impacted cancer clinical research in the past quarter century as much as Mark Green. His expertise in lung cancer and clinical trial design led to the successful completion of seminal studies combining radiation and chemotherapy that forever changed the management of patients with...
